Onabotulinumtoxin-A improves health status and urinary symptoms in subjects with refractory overactive bladder: Real-life experience

Overactive BladderUrinary Incontinence

Long-Term Treatment with OnabotulinumtoxinA Results in Consistent, Durable Improvements in Health-Related Quality of Life in Patients with Overactive Bladder

doi: 10.1016/j.juro.2017.05.068.

Overactive Bladder

Initial clinical experience with selective bladder denervation for refractory overactive bladder

Neurourol Urodyn.

Tu LM, De Wachter S, Robert M, Dmochowski RR, Miller LE, Everaert K

doi: 10.1002/nau.23881.

Overactive Bladder

Overactive bladder symptom bother and health-related quality of life in patients with systemic lupus erythematosus and primary Sjögren syndrome

Lupus.

Pereira E Silva R, Romão VC, Neves M, Garcia R, Oliveira S, Brites J, Ramos FO, Canhão H, Palma Dos Reis J, Pereira da Silva JA, Lopes T

doi: 10.1177/0961203318811605.

Overactive BladderUrinary Tract Infections (UTI)

Onabotulinum toxin A in children with refractory idiopathic overactive bladder: medium-term outcomes

J Pediatr Urol.

Ingham J, Angotti R, Lewis M, Goyal A

doi: 10.1016/j.jpurol.2018.08.007.

Benign Prostatic Hyperplasia (BPH)Lower Urinary Tract Symptoms

Vesomni improves the quality of life in men with lower urinary tract symptoms in routine clinical practice in Europe

Neurourol Urodyn.

Rees J, Foley S, Huang M, Rosa Arias J, Skoumal R, Walters C, Yavuz Y, De Wachter S

doi: 10.1002/nau.23944.

Overactive BladderUrinary Incontinence

Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms

Gynecol Endocrinol.

Schiavi MC, Zullo MA, Faiano P, D'Oria O, Prata G, Colagiovanni V, Giannini A, Di Tucci C, Perniola G, Di Donato V, Monti M, Muzii L, Benedetti Panici P

doi: 10.1080/

Benign Prostatic Hyperplasia (BPH)Lower Urinary Tract Symptoms

Early improvement of storage or voiding symptoms by tadalafil predicts treatment outcomes in patients with lower urinary tract symptoms from benign prostatic hyperplasia

Int J Urol.

Yokoyama O, Ozeki A, Suzuki N, Murakami M

doi: 10.1111/iju.13487.

Endometriosis

Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: Analysis of 2 phase III clinical trials

Am J Obstet Gynecol.

Pokrzywinski RM, Soliman AM, Chen J, Snabes MC, Coyne KS, Surrey ES, Taylor HS

doi: 10.1016/j.ajog.2019.11.1255.

Overactive Bladder

Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)

Health Qual Life Outcomes.

Herschorn S, Staskin D, Tu LM, Fialkov J, Walsh T, Gooch K, Schermer CR

doi: 10.1186/s12955-018-0892-0.

Related content

Long-Term Treatment with OnabotulinumtoxinA Results in Consistent, Durable Improvements in Health-Related Quality of Life in Patients with Overactive Bladder

Initial clinical experience with selective bladder denervation for refractory overactive bladder

Overactive bladder symptom bother and health-related quality of life in patients with systemic lupus erythematosus and primary Sjögren syndrome

Onabotulinum toxin A in children with refractory idiopathic overactive bladder: medium-term outcomes

Vesomni improves the quality of life in men with lower urinary tract symptoms in routine clinical practice in Europe

Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms

Early improvement of storage or voiding symptoms by tadalafil predicts treatment outcomes in patients with lower urinary tract symptoms from benign prostatic hyperplasia

Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: Analysis of 2 phase III clinical trials

Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)